The Number That Matters Is Cost Per Baby, Not Cost Per Cycle

Why cost per cycle misleads

Cost per cycle is the number clinics advertise, but it systematically understates what IVF costs, because a single cycle is not the same as a baby. Most people who succeed with IVF do so across more than one cycle, so paying for 'a cycle' and budgeting for 'a baby' are two different calculations. The first is a menu price; the second is the total you actually spend to bring a child home.

National statistics make this worse if you misread them. Federal ART figures are reported per year and are noncumulative — they count what happened in a single reporting period, not the multi-cycle journey many patients take 3Ref 3Centers for Disease Control and Prevention (2024).NASS Technical Notes.That federal ART national figures are noncumulative and reflect a single reporting year, and how success measures (pregnancy, live-birth delivery, singleton vs multiple) are defined.. And the evidence on repeat cycles is clear that success builds up over several attempts rather than arriving all at once 1Ref 1Smith ADAC, Tilling K, Nelson SM, Lawlor DA (2015).Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles.That IVF live-birth rate is about 29.5% after the first cycle, rising to roughly 65% by the sixth cycle across all ages, but far lower for women aged 40-42 (~12% first cycle, ~31.5% by six) — the basis for multi-cycle, age-adjusted cost planning..

Think of it as the difference between the price of a lottery ticket and the amount you spend before you win. One ticket has a fixed price; the number of tickets a win takes is what determines your real outlay. IVF is not a lottery — the odds are far better and they are grounded in biology, not chance — but the accounting is the same shape: the cost that matters is the price of one attempt multiplied by the attempts a birth takes.

A per-cycle price answers 'what does one attempt cost.' Cost per baby answers the question you actually have.

What cumulative live-birth rate means, and how age changes it

Cumulative live-birth rate is the share of people who have had a baby after a given number of IVF cycles, and it is the single most useful number for cost planning because it tells you how many cycles a birth typically takes. In a large UK study, about 29.5% of women had a live birth after the first cycle, rising to roughly 65% by the sixth cycle across all ages 1Ref 1Smith ADAC, Tilling K, Nelson SM, Lawlor DA (2015).Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles.That IVF live-birth rate is about 29.5% after the first cycle, rising to roughly 65% by the sixth cycle across all ages, but far lower for women aged 40-42 (~12% first cycle, ~31.5% by six) — the basis for multi-cycle, age-adjusted cost planning..

Age bends that curve steeply. In the same data, women aged 40 to 42 had about a 12% live-birth rate in the first cycle and roughly 31.5% by the sixth — less than half the cumulative chance of the group as a whole 1Ref 1Smith ADAC, Tilling K, Nelson SM, Lawlor DA (2015).Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles.That IVF live-birth rate is about 29.5% after the first cycle, rising to roughly 65% by the sixth cycle across all ages, but far lower for women aged 40-42 (~12% first cycle, ~31.5% by six) — the basis for multi-cycle, age-adjusted cost planning.. The practical meaning is direct: the older the eggs, the more cycles a birth tends to require, and more cycles means more cost.

This is why a cumulative success rate across multiple cycles, not a single cycle's per-cycle conception odds, is the figure to plan around. The cumulative success rate is what converts a per-cycle price into an honest per-baby estimate.

Doing the cost-per-baby math

The cost-per-baby math is simple arithmetic once you have two numbers: your clinic's all-in cost for one cycle, and the number of cycles your age and diagnosis are likely to require. Multiply them. If about three in ten first cycles end in a live birth and the odds build toward roughly two in three by the sixth cycle 1Ref 1Smith ADAC, Tilling K, Nelson SM, Lawlor DA (2015).Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles.That IVF live-birth rate is about 29.5% after the first cycle, rising to roughly 65% by the sixth cycle across all ages, but far lower for women aged 40-42 (~12% first cycle, ~31.5% by six) — the basis for multi-cycle, age-adjusted cost planning., a realistic budget plans for more than one attempt, not the best case.

Work it with your own quote rather than a national average. Take the itemized all-in cost of a cycle — the base fee, the IVF medication cost, and the add-ons that apply to you — and weigh it against the cumulative chances for your age band. A younger patient may reach a birth in one or two cycles; an older patient may need several, which is the per-cycle vs cumulative success gap made concrete in dollars.

A worked sketch shows the shape of it. Using the cumulative figures above, the number of cycles behind an average birth changes sharply with age:

These are population averages from the cited study, not a forecast for any one person 1Ref 1Smith ADAC, Tilling K, Nelson SM, Lawlor DA (2015).Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles.That IVF live-birth rate is about 29.5% after the first cycle, rising to roughly 65% by the sixth cycle across all ages, but far lower for women aged 40-42 (~12% first cycle, ~31.5% by six) — the basis for multi-cycle, age-adjusted cost planning., and your clinician can estimate where you actually sit. But the structure is the point: the per-baby cost is the per-cycle price multiplied by a number that grows with age.

The honest version of this estimate is a range, not a single point. But even a rough multiplication reframes the decision away from the sticker on one cycle and toward the total it may take — which is the number worth financing, insuring, and planning around.

Reading national and clinic data without being fooled

Success statistics can be reported several ways, and the denominator changes the number dramatically — which is why two clinics can both quote impressive figures that are not comparable. National data reported by SART breaks outcomes down by patient age band and by whether the rate is measured per egg retrieval, per transfer, or per patient 2Ref 2Society for Assisted Reproductive Technology (SART) (2024).National Summary Report (SART CORS Online).That US national ART outcomes are reported by SART by patient age band and per egg retrieval, per transfer, and per patient — different denominators that change the apparent success rate.. A 'per transfer' rate looks higher than a 'per retrieval' rate for the same care, because it drops the cycles that never reached transfer.

This is the denominator trap, and it is worth learning to spot: per cycle, per transfer, per retrieval, and per patient are four different questions. Federal figures add another caution — they are noncumulative, capturing one reporting year rather than a full course of treatment 3Ref 3Centers for Disease Control and Prevention (2024).NASS Technical Notes.That federal ART national figures are noncumulative and reflect a single reporting year, and how success measures (pregnancy, live-birth delivery, singleton vs multiple) are defined.. In 2021, about 238,126 patients underwent roughly 413,776 ART cycles at reporting clinics, yielding about 91,906 live births — visibly more cycles than babies, precisely because not every cycle ends in a birth 6Ref 6Centers for Disease Control and Prevention (2023).2021 Assisted Reproductive Technology: Fertility Clinic and National Summary Report.That for cycles started in 2021, about 238,126 patients underwent roughly 413,776 ART cycles at 453 reporting clinics, resulting in about 91,906 live births — noncumulative national totals for that year..

Reading a clinic's report well means checking the age band that matches you and the cumulative live birth by cycle number, rather than a single headline percentage chosen because it looks best.

Add-ons that don't lower your cost per baby

An add-on only lowers cost per baby if it raises your chance of a baby, and several of the most expensive ones do not. Paying more per cycle without improving the odds simply raises the price of each attempt — and therefore the total per baby. PGT-A, the genetic screening of embryos, is the clearest example.

In a randomized trial of good-prognosis patients, PGT-A did not improve ongoing-pregnancy rates compared with standard embryo selection by appearance 5Ref 5Munné S, et al. (STAR Study Group) (2019).Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial.That in a randomized trial of good-prognosis patients, PGT-A did not improve ongoing-pregnancy rates versus morphology-based selection for single frozen-thawed transfer.. So for many patients, adding PGT-A raises the per-cycle cost without a matching gain in births, which pushes cost per baby up rather than down. Whether it helps in a specific situation — older patients, or recurrent loss — is a real clinical question, but does PGT-A actually improve IVF success for the average patient is one the evidence answers cautiously.

The same caution applies to the growing menu of laboratory extras sold as ways to improve the odds — additional imaging, specialized culture steps, immune protocols. If an add-on has not been shown to raise the live-birth rate, it can only raise the per-baby cost, because you are paying more for each attempt without buying more births. That is the arithmetic behind treating every proposed extra as a question rather than a default line on the bill.

The general rule holds for any add-on: before it goes on the bill, the question is whether it changes your chance of a live birth, because that is the only thing that changes cost per baby.

Single-embryo transfer and the twin 'bargain' that isn't

Transferring two embryos to 'get it over with' looks like a way to lower cost per baby, but it usually does the opposite once the risks of twins are counted. Guidance recommends elective single-embryo transfer because it reduces multiple gestation while preserving the cumulative live-birth rate, especially for younger patients and euploid embryos 4Ref 4Practice Committees of ASRM and SART (2021).Guidance on the limits to the number of embryos to transfer: a committee opinion.That elective single-embryo transfer reduces multiple gestation while preserving cumulative live-birth rate, especially for younger and euploid-embryo patients..

The economics follow the medicine. A twin pregnancy carries higher risks of preterm birth and the intensive newborn care that comes with it, and those costs — medical and otherwise — can dwarf the price of a second single-embryo transfer later. Two embryos raise the chance of any pregnancy in that one cycle, but a single-embryo transfer, repeated if needed from frozen embryos, reaches a comparable cumulative chance of a healthy baby at far lower total risk.

Choosing one embryo at a time is not settling for lower odds; across cycles it reaches similar success with much less risk to you and the baby.

What actually lowers your cost per baby

The levers that genuinely lower cost per baby are the ones that raise the chance of a birth per dollar spent, and most are about timing and planning rather than a product to buy. Starting younger is the largest: because cumulative success falls with age, the same spending buys a higher chance of a baby earlier. Banking embryos from a retrieval — freezing several for future frozen-embryo transfers — spreads one retrieval's cost across more chances.

A few principles do most of the work:

• Plan for more than one cycle from the start, so the budget matches the number of IVF cycles a birth may realistically take rather than the best case.
• Do not overpay for unproven add-ons, which raise per-cycle cost without reliably raising births.
• Know where diminishing returns set in. Cumulative success keeps rising with more cycles but more slowly, and understanding the diminishing returns after multiple IVF cycles is part of deciding, with your clinician, when to change course.

For anyone weighing fertility preservation, the same math runs forward: the egg freezing age math — freezing younger and banking more eggs — is what makes a future cycle more likely to end in a baby, and so cheaper per baby down the line.

Where a benefit, loan, or refund program fits the per-baby number

None of this math happens in a vacuum, because how you pay changes the effective cost per baby even when the clinic's prices do not. A dollar-capped employer benefit lowers your share of every cycle, so it helps most exactly the patients who need several cycles to reach a birth. A refund or multi-cycle program shifts the cost of the cycles that fail onto the clinic, which is precisely why the per-baby framing matters — those programs are priced against the same cumulative-odds curve you are planning around.

The way to compare any of these is on the per-baby number, not the per-cycle sticker. A financing option that looks cheap per cycle but excludes medications, or that only pays out under a narrow definition of failure, may not lower what you actually spend to bring a baby home. Run every offer through one question: across the cycles my age and diagnosis are likely to require, what does this change about the total?

The right way to judge a benefit, a loan, or a refund program is by what it does to your cost per baby — not to the price of a single cycle.